CRO lapses not expected to hurt India industry

11/28/2004 | Hindu Business Line (India), The

Despite the clinical research organization lapses that led Indian pharmaceutical companies to withdraw their anti-AIDS drugs from the WHO list, CROs in India believe they are about to become major players in the global industry. CRO officials dismiss the lapses, one of which led Ranbaxy to move its CRO business to Europe, as "exceptional instances" that would not adversely affect their business, and a Ranbaxy official agreed the "serious players are quality-driven."

View Full Article in:

Hindu Business Line (India), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC